Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate bioequivalence study in Chinese schizophrenia patients
NCT07268430Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Dec 2023
- Primary completion
- Dec 2024
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Randomised, open-label trial of paliperidone palmitate in schizophrenia (2 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoints: Steady-State Peak Concentration of Paliperidone and Area Under the Concentration-Time Curve over Dosing Interval at Steady State. Started Dec 2023; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT07268430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07268430.